$4.58
0.0150.33%
Últ. Act.: Nov 18, 11:58 AM
Gyre Therapeutics (GYRE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.04 | $-0.12 | 66.7 % |
| Q2 | Aug 7, 2026 | $-0.12 | $-0.06 | -100.0 % |
| Q1 | May 7, 2026 | $-0.05 | $-0.07 | 35.7 % |
| Q4 | Mar 12, 2026 | $0.05 | $0.04 | 15.0 % |
Quarterly Revenue (Billions)
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $32.93M | $28.44M | 15.8 % |
| Q2 | Aug 7, 2026 | $29.11M | $26.44M | 10.1 % |
| Q1 | May 7, 2026 | $22.52M | $32.07M | -29.8 % |
| Q4 | Mar 12, 2026 | $37.20M | $35.83M | 3.82 % |
Gyre Therapeutics (GYRE) publicó su última previsión de noviembre 5, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $100.5M - $111M para el período.
En comparación con la previsión anterior, Gyre Therapeutics mantenido redujo su previsión de ingresos desde un rango anterior de $100.5M - $111M.
Gyre Therapeutics ha emitido 5 actualizaciones de orientación entre el marzo 17, 2025 y el noviembre 5, 2026. During this period, the company lowered its outlook 1 time, signaling management's revised expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | FY '23 |
|---|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||||
| Estimate | $-0.12 | $-0.06 | $-0.07 | $0.04 | — |
| Actual | $-0.04 | $-0.12 | $-0.04 | $0.05 | $-1.41 |
| Surprise | +66.7% | -100.0% | +35.7% | +15.0% | — |
| Revenue | |||||
| Estimate | $28.4M | $26.4M | $32.1M | $35.8M | — |
| Actual | $32.9M | $29.1M | $22.5M | $37.2M | $113.5M |
| Surprise | +15.8% | +10.1% | -29.8% | +3.82% | — |
| Metric | Q4 '26E | Q1 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.08 | $-0.17 |
| Revenue | ||
| Consensus | $29.1M | $22.5M |
